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Abstract
Purpose To perform a formal external validation of the
preoperative Karakiewicz nomogram (KN) for the predic-
tion of cancer-specific survival (CSS) using a large series
of surgically treated patients diagnosed with organ-con-
fined or metastatic renal cell carcinoma (RCC).
Methods Patient population originated from a series of
retrospectively gathered cases that underwent radical or
partial nephrectomy between years 1995 and 2007 for
suspicion of kidney cancer. The original Cox coefficients
were used to generate the predicted risk of CSS at 1, 2, 5,
and 10 years following surgery and compared to the
observed risk of CSS in the current population. External
validation was quantified using measures of predictive
accuracy, defined as model discrimination and calibration.
Results A total of 3,374 patients were identified. Relative
to the original development cohort, the current sample
population had a larger proportion of patients with localized
(40.0 vs. 26.3 %, P\0.001) and non-metastatic (92.2 vs.
88.1 %, P = 0.03) disease at presentation. Model discrimi-
nation for the prediction of CSS was 87.8 % (95 % CI,
84.4–91.4) at 1 year, 87.0 % (95 % CI, 84.4–89.5) at 2 years,
84.7 % (95 % CI, 82.3–87.1) at 5 years, and 85.9 % (95 %
CI, 83.2–88.6) at 10 years. The relationship between predicted
and observed CSS risk was adequate in the calibration plot.
Conclusion The use of the KN for the prediction of CSS
in patients diagnosed with renal cell carcinoma was vali-
dated in the current study. In consequence, this tool may be
recommended for routine clinical counseling in patients
with various stages of RCC in the preoperative setting.
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Introduction
In the last decade, treatment of renal cell carcinoma (RCC)
has significantly improved, and various systems integrating
clinical and pathologic prognostic factors have been pro-
posed to improve the prognostication of patients with
confined or locally advanced RCC. Available prognostic
tools that use pathological variables are considered valu-
able assets in the post-operative counseling and planning of
patients’ follow-up schedule following surgical resection of
the primary tumor. Moreover, some of these tools may be
used in the selection criteria and interpretation of results of
ongoing randomized controlled trials evaluating the effect
of novel targeted therapies in the adjuvant setting [1].
However, the benefit of these tools is not applicable in the
preoperative setting of patients with organ-confined or
advanced RCC who are considered suitable surgical candi-
dates. To date, few prognostic models relying on clinical
variables exist. Two models that combine clinical tumor size
and symptoms showed a model discrimination of less than
70 % in predicting cancer-specific survival (CSS) in patients
with non-metastatic RCC [2, 3]. In patients with advanced
RCC, patient selection among existing targeted therapies is
predominantly based on the risk-group stratification pro-
posed by Motzer et al. [4], which relies on performance
status and other laboratory parameters. However, the mod-
el’s predictive accuracy remains unknown.
Recently, a novel nomogram for the prediction of CSS
in the preoperative setting has been proposed by Kara-
kiewicz et al. [5]. The model relied on patient age, gender,
mode of presentation, clinical tumor size, clinical stage of
the primary tumor, and presence of distant metastases and
showed optimal model discrimination. Since its first
external validation performed on a cohort of 1,972 patients
[6], only one study further tested the predictive accuracy of
this nomogram [7], showing its superiority compared with
the other tested nomograms and risk groups in predicting
survival outcomes in 390 patients with localized RCC.
The aim of the present multicenter study was to perform
an external validation of the preoperative Karakiewicz
nomogram (KN) for the prediction of CSS using a large
series of patients surgically treated for confined or meta-
static RCC.
Materials and methods
Sixteen academic institutions participated to the Surveil-
lance And Treatment Update Renal Neoplasms (SATURN)
project, promoted by the Leading Urological No-profit
foundation Advanced research (LUNA) of the Italian
Society of Urology (SIU) in 2008. A computerized data-
bank was generated for data transfer. The initial database
comprised 5,463 patients who underwent radical nephrec-
tomy (RN) or partial nephrectomy (PN) between 1995 and
2007 for suspicion of kidney cancer. Excluded patients
were those in whom symptom classification (n = 310) or
clinical tumor size (n = 1.789) was missing. These
exclusion criteria resulted in 3,364 assessable patients.
The mode of presentation was defined according to the
Patard classification [8]. Clinical staging of the primary tumor
included a minimum of abdominal computed tomography
(CT) scans and chest X-rays and defined according to the
2002 version of the American Joint Committee on Cancer–
Union Internationale Contre le Cancer TNM classification
[9]. Clinical tumor size, clinical stage of primary tumor, and
presence of distant metastasis were assessed according to
preoperative CT scans. Bone scans and brain CT scans were
obtained only when indicated by signs and symptoms.
Surgery was performed according to the standard crite-
ria for radical nephrectomy, that is, extrafascial dissection
of the kidney. The hilar and regional lymph nodes adjacent
to the ipsilateral renal pedicle were removed along with
enlarged lymph nodes if abnormal on preoperative CT
scans or palpable intraoperatively. Extended lymphade-
nectomy was routinely performed only in few centers. In
patients with contralateral normal kidney, elective neph-
ron-sparing surgery had been routinely indicated in the
presence of single, peripheral tumors B4 in size, although
some referral centers perform elective nephron-sparing
surgery also in case of larger tumors. Imperative nephron-
sparing surgery had been performed in patients with
bilateral tumors or with neoplasia involving anatomically
or functionally solitary kidneys. Nephron-sparing surgery
was performed in the form of enucleoresection, simple
enucleation, or polar nephrectomy according to the clinical
indications and surgeon’s preference.
Patients were generally observed every 3–4 months for
the first year after surgery, every 6 months from the second
through the fifth years, and annually thereafter. Follow-up
consisted of a history, physical examination, routine blood
work and serum chemistry studies, chest radiography, and
radiographic evaluation of the contralateral or remnant
kidney. Elective bone scan, chest computed tomography,
and magnetic resonance imaging were performed when
clinically indicated.
The cause of death was determined by the treating phy-
sicians, by chart review corroborated by death certificates, or
by death certificates alone. Most patients who were identi-
fied as having died of kidney cancer had progressive, widely
disseminated metastases at the time of death.
Statistical analyses
Baseline descriptives were reported using median and
interquartile range or using mean ± standard deviation for
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continuously coded variables, and frequencies and pro-
portions for categorically coded variables. Kaplan–Meier
plots graphically explored CSS rates. The original Cox
regression coefficients were used to generate the predicted
risk when relying on the Karakiewicz nomogram and
compared with the observed risk of mortality at 1, 2, 5, and
10 years in the current sample population. Model dis-
crimination represents an unbiased measure to discriminate
among patients, which was quantified using the area under
the receiver operating characteristic curve [10]. A value of
100 % indicates perfect predictions, whereas 50 % is
equivalent to a toss of a coin. With censored data, the
calculation [11] is slightly modified. However, its inter-
pretation remains the same. It represents the probability
that, for a randomly selected pair of patients, the model is
capable to discriminate who had a higher risk of the event,
hereby death. This methodology was previously used in
established publications [12]. The 95 % confidence inter-
vals were computed using 200 bootstrap resampling.
Finally, the relationship between predicted and observed
rates was assessed using methods of calibration and
graphically explored using the val.surv function.
All reported P values were two-sided with a significance
level set at P \ 0.05. Statistical analyses were performed
with SPSS vers. 16.0 (SPSS Inc, Chicago, IL, USA), S-Plus
Professional software (MathSoft, Inc., Washington, USA),
and SAS (version 9.0, North Carolina, USA).
Results
The descriptive characteristics of the 3,364 analyzed
patients are listed in Table 1. Median age was 63 years
(interquartile range, 54–71). Notably, only 261 patients
(7.8 %) had synchronous distant metastases at diagnosis. In
total, 2,354 (70 %) patients underwent radical nephrec-
tomy, and 1,010 (30 %) patients underwent nephron-spar-
ing surgery. Relative to the original development cohort
(n = 2,474), the current population had more asymptom-
atic patients (68.2 vs. 48.2 %, P \ 0.001). Moreover, most
patients were T1a (40.0 vs. 26.3 %, P \ 0.001) and non-
metastatic (92.1 vs. 88.1 %, P = 0.03) in the current series.
At median follow-up of 48 months (IQR, 26–85), 2,530
patients were alive and disease-free.
The 1-, 2-, 5-, and 10-year CSS probabilities were
96.5 % (95 % confidence interval [CI], 95.8–97.1), 92.1 %
(95 % CI, 91.1–93.0), 84.8 % (95 % CI, 83.4–86.2), and
79.4 % (95 % CI, 77.3–81.6), respectively (Fig. 1a).
Table 2 shows the results of univariable and multivariable
Cox regression analyses for the prediction of CSS. Notably,
all variables included in the original preoperative KN
emerged as independent predictors of CSS .
Model discrimination for the prediction of CSS was
87.8 % (95 % CI, 84.4–91.4) at 1 year, 87.0 % (95 % CI
84.4–89.5) at 2 years, 84.7 % (95 % CI 82.3–87.1) at
5 years, and 85.9 % (95 % CI 83.2–88.6) at 10 years.
Overall, the model was well calibrated, although it dem-
onstrated an overall tendency to overestimate the risk of
CSS between 2 and 15 % (Fig. 1b).
Discussion
The current study is a formal external validation of the
preoperative KN performed on an independent European
multicentre series of patients diagnosed with confined or
synchronous metastatic RCC. The model discrimination
observed in our cohort is similar to the one originally
reported in the external validation cohort of 1,972 patients
used by Karakiewicz et al. [5]. Specifically, the 5- and
10-year model discrimination accuracies were 86.8
and 84.2 % in the initial external validation and 84.7 and
85.9 % in the current study, respectively.
Several important considerations should be mentioned
in regard to the characteristics of our cohort in comparison
with that of the one previously used by Karakiewicz et al.
to develop the nomogram (n = 2,474), as well as the one
Table 1 Descriptive characteristics of 3,364 patients from the
external validation cohort and 2,474 patients from the previous
development cohort
Predictors External validation
cohort (n = 3,364)
Development cohort
(n = 2,474) [5]
Age (year)
Mean (median) 61.6 (63.0) 60.7 (62.0)
Range 7–92 10–91
Symptoms
Asymptomatic 2,293 (68.2) 1,142 (46.2)
Local 946 (28.1) 879 (35.5)
Systemic 125 (3.7) 453 (18.3)
Gender
Male 2,207 (65.6) 1,648 (66.6)
Female 1,157 (34.4) 826 (33.4)
Tumor size (cm)
Mean (median) 5.6 (5.0) 6.6 (6.0)
Range 1–22 0.5–25
T stage
T1a 1,354 (40.0) 650 (26.3)
T1b 1,108 (32.9) 565 (22.8)
T2 585 (17.4) 359 (14.5)
T3 326 (9.7) 900 (36.4)
Metastases
M0 3,103 (92.2) 2,179 (88.1)
M1 261 (7.8) 295 (11.9)
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used to perform the external validation (n = 1,972) in the
original study. Specifically, prevalence of symptoms, mean
clinical tumor size, and clinical stage were more unfavor-
able in the original development cohort in comparison with
both external validations cohorts (Table 1). The 5- and
10-year CSS rates were 84.8 versus 75.4 % and 79.4 versus
68.3 % in the current cohort relative to the original devel-
opment cohort, respectively. This may represent a potential
explanation for the model’s overall tendency to overestimate
the predictions in the current external validation.
In order to tailor treatment based on individual patients’
needs, it is essential for physicians to have the ability to
predict the biological aggressiveness of these neoplasms
and to stratify patients into risk groups for risk of recur-
rence, progression, and death. Defining risk groups is very
useful for routine clinical patient counseling, selection of
treatment options, scheduling of follow-up, and in selection
of patients for participation in clinical trials. The most
useful models are probably those able to assist physicians
in treatment choices before therapy is determined, partic-
ularly in light of the new therapies currently become
available or being tested for RCC.
Our results strongly support the use of preoperative KN
for the prediction of CSS probabilities both in patients with
organ-confined or advanced RCC. In a similar setting,
Yayciouglu et al. [2] and Cindolo et al. [3] proposed two
models for the prediction of recurrence in patients with non-
metastatic RCC. In the former, authors identified patient
presentation (symptomatic vs. incidental), as well as clinical
size as important prognostic predictors of treatment failure.
In the latter, authors proposed the use of clinical presenta-
tion, clinical size, TNM, and cellular grade for the prediction
of recurrence. Unfortunately, given the lack of information
on several variables that were integrated in these models
within the current database, we could not externally validate
such models. Nonetheless, previous external validation data
from a multi-institutional study revealed a 5-year discrimi-
nation accuracy of 62 % for the Yayciouglu model and
64 % for the Cindolo score [13].
In the context of patients with synchronous distant
metastases, the most commonly used tool to predict overall
survival is the Memorial Sloan–Kettering Cancer Center
(MSKCC) classification, which includes Karnofsky per-
formance status, lactate dehydrogenase, hemoglobin, cor-
rected calcium, and interval from the initial diagnosis to
therapy. According to the Motzer criteria, patients with
advanced RCC can be subdivided in low-(0 risk factors),
intermediate-(1–2 risk factors), and high-risk (3–5 risk
factors) categories [4]. Although this classification has
been widely used, it was never subjected to measures of
predictive accuracy. Moreover, its applicability in the tar-
geted therapy era is limited [14]. While the Motzer criteria
may be appropriate for risk-group stratification, they might
not be adequate in the estimation of CSS in individual
cases. The preoperative KN could represent a useful tool in
this setting.
In patients with advanced disease, an attractive future
perspective could be the improvement of prognostic
accuracy of preoperative KN adding traditional histopa-
thological, molecular, or cytogenetic information coming
from the renal tumor biopsies of the primary tumor.
Unfortunately, percutaneous renal tumor biopsy has still a
limited role in the clinical workup of patients with renal
parenchymal tumors, although improvements in the tech-
nique significantly reduced the risk of tumor spread and
complications.
As KN relies on the old TNM staging 6th edition (2002),
the nomogram could be potentially affected by the new
TNM classification 7th edition (2010) [15]. From the 6th to
Fig. 1 a Cancer-specific survival probabilities in patients included in
the analysis. b Calibration plot depicting the relationship between the
nomogram-predicted CSS probabilities (x-axis) and the actual fraction
surviving (y-axis) within the current external validation cohort
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the 7th edition, however, the only modifications were to
subclassify T2 tumors into T2a and T2b and to redefine the
distinction between T3a and T3b, and KN does not con-
sider T2 and T3 subclassifications.
Despite the strengths of the current report, limitations do
apply. First, the retrospective nature of the study may have
induced bias above all in the correct evaluation of clinical
stage of primary tumor. Second, the current validation
cohort originated from several institutions in Italy. Third,
the exclusion of missing data reduced the number of
patients that were assessed. Results may have differed if
missing data were handled differently.
Conclusions
The preoperative KN uses the combination of common
clinical information such as age, gender, symptoms, clini-
cal tumor size and stage, and the presence of distant
metastases to accurately predict the 1-, 2-, 5-, and 10-year
CSS of patients with renal cell carcinoma. The current
study originating from a multi-institutional series con-
firmed the benefit of this nomogram using measures of
predictive accuracy, defined as model discrimination and
calibration.
In consequence, the nomogram is considered a valuable
tool for physicians and patients in the preoperative setting.
Its predictions may be used to provide a framework for
comparisons between nephrectomy and alternative treat-
ment modalities for all stages of RCC.
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